Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study
Standard
Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study : Rationale and design of the international Cryo-FIRST study. / Hermida, Jean Sylvain; Chen, Jian; Meyer, Christian; Iacopino, Saverio; Arena, Giuseppe; Pavlovic, Nikola; Velagic, Vedran; Healey, Stewart; Packer, Douglas L; Pitschner, Heinz-Friedrich; de Asmundis, Carlo; Kuniss, Malte; Chierchia, Gian Battista.
In: AM HEART J, Vol. 222, 01.04.2020, p. 64-72.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study
T2 - Rationale and design of the international Cryo-FIRST study
AU - Hermida, Jean Sylvain
AU - Chen, Jian
AU - Meyer, Christian
AU - Iacopino, Saverio
AU - Arena, Giuseppe
AU - Pavlovic, Nikola
AU - Velagic, Vedran
AU - Healey, Stewart
AU - Packer, Douglas L
AU - Pitschner, Heinz-Friedrich
AU - de Asmundis, Carlo
AU - Kuniss, Malte
AU - Chierchia, Gian Battista
N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - BACKGROUND: Radiofrequency current (RFC) catheter ablation for patients with paroxysmal atrial fibrillation (AF) has been shown to be safe and effective in first-line therapy. Recent data demonstrates that RFC ablation provides better clinical outcomes compared to antiarrhythmic drug (AAD) in the treatment of early AF disease. Furthermore, studies comparing RFC and cryoballoon have established comparable efficacy and safety of pulmonary vein isolation (PVI) for patients with symptomatic paroxysmal AF.OBJECTIVES: The Cryo-FIRST trial was designed to compare AAD treatment against cryoballoon PVI as a first-line therapy in treatment naïve patients with AF. Efficacy and safety will be compared between the two cohorts and amongst subgroups.METHODS: The primary hypothesis is that cryoablation is superior to AAD therapy. To test this hypothesis, patients will be randomized in a 1:1 design. Using a 90-day blanking period, primary efficacy endpoint failure is defined as (at least) one episode of atrial arrhythmia with a duration >30 sec (documented by 7-day Holter or 12-lead ECG). Secondary endpoints (Quality-of-Life, rehospitalization, arrhythmia recurrence rate, healthcare utilization, and left atrial function) and adverse events will also be evaluated. Study enrollment will include 218 patients in up to 16 centers.CONCLUSIONS: This study will be a multi-national randomized controlled trial comparing cryoablation against AAD as a first-line treatment in patients with paroxysmal AF. The results may help guide the selection of patients for early AF disease therapy via cryoballoon ablation.
AB - BACKGROUND: Radiofrequency current (RFC) catheter ablation for patients with paroxysmal atrial fibrillation (AF) has been shown to be safe and effective in first-line therapy. Recent data demonstrates that RFC ablation provides better clinical outcomes compared to antiarrhythmic drug (AAD) in the treatment of early AF disease. Furthermore, studies comparing RFC and cryoballoon have established comparable efficacy and safety of pulmonary vein isolation (PVI) for patients with symptomatic paroxysmal AF.OBJECTIVES: The Cryo-FIRST trial was designed to compare AAD treatment against cryoballoon PVI as a first-line therapy in treatment naïve patients with AF. Efficacy and safety will be compared between the two cohorts and amongst subgroups.METHODS: The primary hypothesis is that cryoablation is superior to AAD therapy. To test this hypothesis, patients will be randomized in a 1:1 design. Using a 90-day blanking period, primary efficacy endpoint failure is defined as (at least) one episode of atrial arrhythmia with a duration >30 sec (documented by 7-day Holter or 12-lead ECG). Secondary endpoints (Quality-of-Life, rehospitalization, arrhythmia recurrence rate, healthcare utilization, and left atrial function) and adverse events will also be evaluated. Study enrollment will include 218 patients in up to 16 centers.CONCLUSIONS: This study will be a multi-national randomized controlled trial comparing cryoablation against AAD as a first-line treatment in patients with paroxysmal AF. The results may help guide the selection of patients for early AF disease therapy via cryoballoon ablation.
KW - Ablation Techniques/methods
KW - Anti-Arrhythmia Agents/therapeutic use
KW - Atrial Fibrillation/physiopathology
KW - Atrial Function, Right/physiology
KW - Cryosurgery/methods
KW - Electrocardiography
KW - Female
KW - Follow-Up Studies
KW - Heart Conduction System/physiopathology
KW - Humans
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Pulmonary Veins/surgery
KW - Quality of Life
KW - Recurrence
KW - Single-Blind Method
KW - Treatment Outcome
U2 - 10.1016/j.ahj.2019.12.006
DO - 10.1016/j.ahj.2019.12.006
M3 - SCORING: Journal article
C2 - 32018203
VL - 222
SP - 64
EP - 72
JO - AM HEART J
JF - AM HEART J
SN - 0002-8703
ER -